You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Details for New Drug Application (NDA): 205029


✉ Email this page to a colleague

« Back to Dashboard


NDA 205029 describes EPINEPHRINE, which is a drug marketed by Armstrong Pharms, Am Regent, Bpi Labs, Intl Medication Sys, Hospira, and Teva Pharms Usa, and is included in eight NDAs. It is available from nine suppliers. There are three patents protecting this drug. Additional details are available on the EPINEPHRINE profile page.

The generic ingredient in EPINEPHRINE is epinephrine. There are twenty-one drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the epinephrine profile page.
Summary for 205029
Tradename:EPINEPHRINE
Applicant:Bpi Labs
Ingredient:epinephrine
Patents:3
Suppliers and Packaging for NDA: 205029
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EPINEPHRINE epinephrine SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS 205029 NDA Henry Schein, Inc. 0404-9857 0404-9857-01 1 AMPULE in 1 BAG (0404-9857-01) / 1 mL in 1 AMPULE
EPINEPHRINE epinephrine SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS 205029 NDA A-S Medication Solutions 50090-3039 50090-3039-0 25 AMPULE in 1 BOX (50090-3039-0) / 1 mL in 1 AMPULE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUSStrength1MG/ML (1MG/ML)
Approval Date:Jul 29, 2014TE:RLD:Yes
Patent:⤷  Sign UpPatent Expiration:Aug 14, 2034Product Flag?YSubstance Flag?Delist Request?Y
Patented Use:EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE 1), INCLUDING ANAPHYLAXIS; A METHOD OF TREATING ALLERGIC REACTION, ANAPHYLAXIS, ANAPHYLACTIC SHOCK, OR COMBINATION THEREOF BY AN INJECTION OF AT LEAST ONE DOSAGE OF THE INJECTABLE LIQUID PHARMACEUTICAL
Patent:⤷  Sign UpPatent Expiration:Aug 14, 2034Product Flag?Substance Flag?Delist Request?Y
Patented Use:INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK
Patent:⤷  Sign UpPatent Expiration:Aug 15, 2034Product Flag?YSubstance Flag?Delist Request?Y
Patented Use:EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.